Heron Neutron Medical Corp. — Advancing a New Era of AB-BNCT Precision Treatment
In cancer care, progress in medical technology remains a critical driver of hope. Guided by the core value of “Precision Care for Renewed Life,” Heron Neutron Medical Corp. focuses on the research, development, and deployment of accelerator-based boron neutron capture therapy (AB-BNCT), with the objective of expanding breakthrough treatment options for patients worldwide. Through continuous innovation and system integration, the Company has established an emerging leadership position internationally and demonstrates distinctive competitive strengths.
World-Class Technology, Innovation-Led Future
Heron concentrates on two core domains—accelerator based neutron source technology and clinical application of BNCT—and has developed an advanced AB-BNCT system. Compared with reactor-based neutron sources, the Company’s accelerator-based BNCT system features a smaller footprint, enhanced operational safety, significantly reduced construction and maintenance costs, thereby enabling broader clinical deployment of BNCT.
Backed by a multidisciplinary team spanning physics, engineering, and clinical, Heron emphasizes quality, safety, and clinical utility throughout product development, enabling the Company to maintain strong technological maturity and applicability in healthcare settings.
The World’s Only Total Solution Provider
Heron is distinctively positioned with in-house capabilities spanning both the AB-BNCT system and boron-containing therapeutic agents. This integration enables the Company to provide hospitals and research institutions with coordinated device-and-drug solutions designed to support treatment effectiveness.
Heron’s flexible commercialization models—including equipment sales, technology licensing, and collaborative treatment center development—allow the Company to tailor arrangements to partner needs and clinical requirements, accelerating market rollout in different regions.
Therapeutic Breakthroughs of AB-BNCT
The overarching goal of cancer therapy is not only to extend life but also to improve quality of life. AB-BNCT is aligned with these aims through its focus on precision and treatment burden reduction:
1. Precision Targeting of Tumors
AB-BNCT administers a boron-containing agent with preferential accumulation in tumor cells. Under neutron irradiation, high-linear-energy-transfer particles are generated in situ within the tumor microenvironment, selectively damaging malignant cells while sparing surrounding healthy tissues.
2. Reduced Side Effects
Relative to conventional radiotherapy or chemotherapy, AB-BNCT is designed to mitigate treatment-related adverse effects, supporting the maintenance of daily function and overall quality of life for patients.
3. Streamlined Course of Care
Owing to its treatment efficiency, AB-BNCT may achieve clinically meaningful tumor control with one or a limited number of sessions in suitable cases, offering an additional option for patients with recurrent tumors.
Building on these attributes, Heron’s AB-BNCT solutions have begun to demonstrate encouraging clinical outcomes and are attracting growing attention from the professional community.
Shaping a New Paradigm in Global Cancer Care
Confronting a shared global challenge, Heron continues to advance the international clinical deployment and adoption of AB-BNCT through innovative technology, integrated solutions, and a patient-centric mission. Leveraging its technical strengths, end-to-end capabilities, and proven clinical value, the Company is progressing toward becoming a trusted leader in the BNCT field. Looking ahead, Heron will continue to use technology as a bridge to broaden access to advanced therapy and improve both outcomes and quality of life for more cancer patients.